Multiple factors affect injecting drug-related mortality, many of which will vary over time and between jurisdictions. There are relatively few studies of mortality among injecting drug users (IDU) in Australia. We aimed to provide data comparable to those reported internationally on the rate of mortality among IDU in Australia. We retrospectively examined mortality among participants (N=220) from the first Australian cohort study of IDU by linking coded personal identifier records with a national death register. The overall mortality rate among those followed-up was 0.83 per 100 PY (95% CI, 0.56-1.21 per 100 PY). This rate is lower than those reported internationally but comparable to the limited Australian data from other cohorts of IDU. Mortality was higher among males, most common among those aged in their early thirties and drug-related mortality occurred typically after substantial injecting careers. Extensive experience of incarceration (>or=3 times) was associated with increased risk of mortality. These results suggest that rates of mortality among Australian IDU may be lower than those reported internationally, with low HIV prevalence and Australia's long-held harm reduction framework potentially contributing to this result. Further studies using defined cohorts followed over time are needed to examine long-term outcomes among IDU in Australia.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.drugalcdep.2008.03.006 | DOI Listing |
Bioresour Technol
January 2025
Research Center For Sustainable Production System and Life Cycle Assessment, National Research and Innovation Agency (BRIN), KST BJ Habibie, Building 720 Puspiptek Area, South Tangerang, Banten 15314, Indonesia. Electronic address:
Anaerobic digestate animal effluent (ADAE) contains high N and P nutrients which need to be treated. In this study, an integrated process was proposed using a microalgae consortium of Chlorella and Scenedesmus. The system was designed for 71 m/d (medium-sized) and 355 m/d (large-sized) animals of ADAE.
View Article and Find Full Text PDFInt J Drug Policy
November 2024
Faculty of Medicine, School of Health Sciences, University of Iceland, Iceland; Department of Infectious Diseases, Landspitali University Hospital, Iceland; Department of Science, Landspitali University Hospital, Reykjavik, Iceland.
Background: Limited data exists about treatment outcomes in nationwide hepatitis C virus (HCV) elimination programs where injection drug use (IDU) is the main mode of transmission. In 2016 Iceland initiated the HCV elimination program known as Treatment as Prevention for Hepatitis C (TraP HepC). Factors associated with HCV cure in this population are examined.
View Article and Find Full Text PDFIntern Med J
December 2024
Department of Infectious Diseases, Royal Perth Hospital, Perth, Western Australia, Australia.
Background: Infective endocarditis (IE) is a severe infection with considerable mortality. It is associated with geographical variation, complicating diagnosis and treatment of patients in a standardised manner.
Aim: To evaluate the characteristics and management outcomes of patients with IE in Royal Perth Hospital (RPH).
Int J Drug Policy
August 2024
The Kirby Institute, University of New South Wales, Australia; Centre for Social Research in Health, University of New South Wales, Australia.
Background: Hepatitis C virus (HCV) is a significant concern within prison populations. Provision of HCV testing and treatment for people in prison is expanding and a key component of global elimination efforts. Despite growing service availability, several challenges remain in HCV testing and treatment engagement during incarceration.
View Article and Find Full Text PDFViruses
June 2024
Barwon South West Public Health Unit, Barwon Health, Geelong 3220, Australia.
Increasing testing is key to achieving hepatitis C elimination. This retrospective study aimed to assess the testing cascade of patients at a regional hospital in Victoria, Australia, who inject drugs or are living with hepatitis C, to identify missed opportunities for hepatitis C care. Adult hospital inpatients and emergency department (ED) attendees from 2018 to 2021 with indications for intravenous drug use (IDU) or hepatitis C on their discharge or ED summary were included.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!